Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization

6 marzo 2017 aggiornato da: Nan Jiang

Effects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation Embolization

Aim of this trial is to study the effect of Dexmedetomidine on post-operative blood pressure in patients undergoing brain arteriovenous malformation embolization. The patients were randomized allocated to either Dexmedetomidine group or Control group. Patients in Dexmedetomidine group will receive intravenous Dexmedetomidine while the control group will receive normal saline. Post-operative anti-hypertensive drug, Visual analogue score,post-operative analgesics consumption, Quality of Recovery score, Ramsay score, and adverse events were recorded.

Panoramica dello studio

Stato

Sconosciuto

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Aim of this trial is to study the effect of Dexmedetomidine on post-operative blood pressure in patients undergoing brain arteriovenous malformation embolization. The patients were randomized allocated to either Dexmedetomidine group or Control group according to a random number. Patients in Dexmedetomidine group will receive intravenous Dexmedetomidine while the control group will receive normal saline. Post-operative anti-hypertensive drug, Visual analogue score,post-operative analgesics consumption, Quality of Recovery score-15 items, Ramsay score, and adverse events were recorded.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Cina
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510080
        • Reclutamento
        • the First Affiliated Hospital of Sun Yetsen University
        • Contatto:
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • patients undergoing brain arteriovenous malformation embolization in the fist affiliated hospital, Sun Yat-sen University, aged 18-65 years, available to chat with,and the tracheal tube was extubated after surgery immediately.

Exclusion Criteria:

  • abuse anesthetic analgesics and sedative drugs, or allergic to Dexmedetomidine or other anesthetics, hypotension or bradycardia before surgery, severe pulmonary disease with saturation of pulse oximetry less than 90% before surgery, or patients refused to attend in this study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dexmedetomidine
Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
Droga: Dexmedetomidine
1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
Altri nomi:
  • DEX
Comparatore placebo: Control group
Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
Altro: normal saline
equal volume of normal saline was administered intravenously constantly after tracheal extubation.
Altri nomi:
  • NS

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
urapidil consumption
Lasso di tempo: the end of the 6th hour after tracheal extubation
urapidil consumption was recorded by nurses every hour
the end of the 6th hour after tracheal extubation

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
urapidil consumption on POD1
Lasso di tempo: the total consumption of urapidil on post-operative day 1.
urapidil consumption was recorded by nurses every hour
the total consumption of urapidil on post-operative day 1.
urapidil consumption on POD2
Lasso di tempo: the total consumption of urapidil on post-operative day 2.
urapidil consumption was recorded by nurses every hour
the total consumption of urapidil on post-operative day 2.
Visual Analogue score
Lasso di tempo: the end of the 6th hour after tracheal extubation
visual analogue score was measured by visual analogue scale
the end of the 6th hour after tracheal extubation
Visual Analogue score at 24th hour
Lasso di tempo: the end of the 24th hour after tracheal extubation
visual analogue score was measured by visual analogue scale
the end of the 24th hour after tracheal extubation
Visual Analogue score at 48th hour
Lasso di tempo: the end of the 48th hour after tracheal extubation
visual analogue score was measured by visual analogue scale
the end of the 48th hour after tracheal extubation
Quality of Recovery Score
Lasso di tempo: the end of the 6th hour after tracheal extubation
Quality of Recovery Score was measured by a 15-item quality of recovery scale
the end of the 6th hour after tracheal extubation
Quality of Recovery Score at 24th hour
Lasso di tempo: the end of the 24th hour after tracheal extubation
Quality of Recovery Score was measured by a 15-item quality of recovery scale
the end of the 24th hour after tracheal extubation
Quality of Recovery Score at 48th hour
Lasso di tempo: the end of the 48th hour after tracheal extubation
Quality of Recovery Score was measured by a 15-item quality of recovery scale
the end of the 48th hour after tracheal extubation
Analgesics consumption
Lasso di tempo: the end of the 6th hour after tracheal extubation
Analgesics consumption was recorded by nurse every hour
the end of the 6th hour after tracheal extubation
Analgesics consumption on POD1
Lasso di tempo: the total consumption of urapidil on post-operative day 1.
Analgesics consumption was recorded by nurse every hour
the total consumption of urapidil on post-operative day 1.
Analgesics consumption on POD2
Lasso di tempo: the total consumption of urapidil on post-operative day 2.
Analgesics consumption was recorded by nurse every hour
the total consumption of urapidil on post-operative day 2.
Bradycardia
Lasso di tempo: the end of the 6th hour after tracheal extubation
a heart rate of lower than 50 beats per minute was identified as bradycardia, frequency of bradycardia was recorded by nurse
the end of the 6th hour after tracheal extubation
Bradycardia at 24th hour
Lasso di tempo: the end of the 24th hour after tracheal extubation
a heart rate of lower than 50 beats per minute was identified as bradycardia, frequency of bradycardia was recorded by nurse
the end of the 24th hour after tracheal extubation
Bradycardia at 48th hour
Lasso di tempo: the end of the 48th hour after tracheal extubation
a heart rate of lower than 50 beats per minute was identified as bradycardia, frequency of bradycardia was recorded by nurse
the end of the 48th hour after tracheal extubation
PONV
Lasso di tempo: the end of the 6th hour after tracheal extubation
post-operative nausea and vomiting (PONV) was recorded by nurse
the end of the 6th hour after tracheal extubation
PONV at 24th hour
Lasso di tempo: the end of the 24th hour after tracheal extubation
post-operative nausea and vomiting (PONV) was recorded by nurse
the end of the 24th hour after tracheal extubation
PONV at 48th hour
Lasso di tempo: the end of the 48th hour after tracheal extubation
post-operative nausea and vomiting (PONV) was recorded by nurse
the end of the 48th hour after tracheal extubation

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Nan Jiang

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 gennaio 2016

Completamento primario (Anticipato)

31 dicembre 2017

Completamento dello studio (Anticipato)

31 dicembre 2017

Date di iscrizione allo studio

Primo inviato

6 marzo 2017

Primo inviato che soddisfa i criteri di controllo qualità

6 marzo 2017

Primo Inserito (Effettivo)

9 marzo 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 marzo 2017

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 marzo 2017

Ultimo verificato

1 marzo 2017

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • NJiang2016-001

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

the IPD will not be shared with others, since following investigations based on this trial is about to start.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Dexmedetomidine

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in United Arab Emirates

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi